These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2397009)

  • 1. Disposition and effect of the new thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid in man.
    Tanaka M; Ono K; Hakusui H; Takegoshi T; Shiozawa T; Nii S; Shibata H
    Arzneimittelforschung; 1990 Jun; 40(6):712-5. PubMed ID: 2397009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904), in man after single oral administration.
    Tanaka M; Ono K; Takegoshi T; Shiozawa T; Suzuki T; Nii S; Shibata H
    J Pharm Pharmacol; 1989 Oct; 41(10):680-4. PubMed ID: 2575144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in human plasma and urine using solid-phase extraction and high-performance liquid chromatography.
    Tanaka M; Ono K; Takegoshi T
    J Chromatogr; 1988 Apr; 426(1):111-9. PubMed ID: 3384863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in man after repeated oral doses.
    Tanaka M; Ono K; Hakusui H; Takegoshi T; Shiozawa T; Suzuki T; Nii S; Shibata H
    J Pharm Pharmacol; 1990 Jul; 42(7):491-5. PubMed ID: 1980290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model.
    Zheng NX; Sato H; Adachi I; Horikoshi I
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):285-93. PubMed ID: 9074892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
    Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
    J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of DP-1904 and its ester glucuronide in human urine and determination of their enantiomeric compositions by high-performance liquid chromatography with optical activity and ultraviolet detection.
    Tanaka M; Ono K; Hakusui H; Takegoshi T; Watanabe Y; Kanao M
    Drug Metab Dispos; 1990; 18(5):698-703. PubMed ID: 1981723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo glucuronidation in rat and humans of 5,6-dihydro-7-(1H-imidazol-1-yl)-naphthalene-2-carboxylic acid, a selective inhibitor of thromboxane synthase.
    Thomassin J; Battaglia R; Allievi C; Castelli MG; Strolin Benedetti M
    Drug Metab Dispos; 1993; 21(1):151-5. PubMed ID: 8095210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 2nd communication: absorption, distribution and excretion after single and consecutive subcutaneous administration in rats.
    Mizojiri K; Okabe H; Sugeno K; Esumi Y; Takaichi M; Tsutsumi S; Harada T; Miyoshi R; Inaba A
    Arzneimittelforschung; 1997 Feb; 47(2):195-200. PubMed ID: 9079240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.
    Siefert HM; Maruhn D; Maul W; Förster D; Ritter W
    Arzneimittelforschung; 1986 Oct; 36(10):1496-502. PubMed ID: 3814211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of thromboxane A2 synthetase inhibitor, DP-1904 on the action of vasoactive substances in rabbit blood vessel smooth muscle preparations].
    Shimizu K; Kobayashi J; Iwanaga T; Kuratomi Y; Kitamura S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 May; 27(5):591-6. PubMed ID: 2615099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers.
    Gatti G; Bartoli A; Bertin D; Strolin-Benedetti M; Perucca E
    Eur J Clin Pharmacol; 1994; 47(3):275-80. PubMed ID: 7867681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
    Chiabrando C; Broggini M; Castelli MG; Cozzi E; Castagnoli MN; Donelli MG; Garattini S; Giavazzi R; Fanelli R
    Cancer Res; 1987 Feb; 47(4):988-91. PubMed ID: 3100032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I dose-ranging safety and pharmacokinetics study of a novel oral thromboxane synthase inhibitor, FCE 22, 178.
    Li RC; Narang PK; Lewis RC; Hatfield NZ; Rossi DT; Colborn DC
    J Clin Pharmacol; 1993 Apr; 33(4):373-80. PubMed ID: 8473553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats.
    Nagao T; Ito M; Nagamatsu T; Suzuki Y
    Eur J Pharmacol; 1994 Jul; 259(3):233-42. PubMed ID: 7982449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of thromboxane A2 synthetase inhibitor, DP-1904 on the action of vasoactive substances in guinea pig trachea and lung tissue strips].
    Shimizu K; Kobayashi J; Iwanaga T; Kuratomi Y; Kitamura S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Mar; 27(3):339-44. PubMed ID: 2615088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.